Journal
BLOOD
Volume 140, Issue 8, Pages 804-805Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2022016866
Keywords
-
Categories
Funding
- Janssen Pharmaceutical Company of Johnson Johnson
- Bayer Life Sciences Company
Ask authors/readers for more resources
The study published in Blood presents the results of PROLAPS-II trial, which investigated the efficacy and safety of extended prophylaxis with rivaroxaban after laparoscopic surgery for colorectal cancer.
Reduction of thrombotic risk after surgery is a long-established clinical practice standard, but evidence is lacking in some specific settings. In this issue of Blood, Becattini et al(1) publish the results of PROLAPS-II, a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of extended prophylaxis with rivaroxaban after laparoscopic surgery for colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
